Perioperative medicine & outcomes
Palonosetron as prophylaxis for post-discharge nausea and vomiting: a prospective, randomised, double-blind, placebo-controlled trial in ambulatory surgery
Primary result · Complete response until POD 2Result — go to the resultOdds ratio 1.69 95% CI 0.85–3.37Authors' conclusion
Compared with placebo, palonosetron did not reduce the overall incidence of post-discharge nausea and vomiting up to postoperative day 2.
Study context
- Population
- Male and female ambulatory surgery patients under GA with a high predicted risk for post-discharge nausea and vomiting (PDNV)
- Participants
- 170 participants
- Comparison
- Palonosetron 75 μg i.v. vs normal saline before discharge
- Palonosetronn = 84
- Placebon = 86reference
- Primary endpoint
- Complete response (no nausea, vomiting, or use of rescue medication)
- Follow-up
- Until POD 2
Methodological detailsprospective, double-blind, placebo-controlled, Outcomes measured by patient questionnaire during the first 3 postoperative days (PODs)
- Prospective
- Double-blind
- Placebo-controlled
- Outcomes measured by patient questionnaire during the first 3 PODs
Primary result
Complete response until POD 2
Odds ratio
1.69
95% CI 0.85–3.37
P = 0.131
Events by treatment group
Palonosetron vs Placebo
OR 1.69 (95% CI 0.85–3.37); P = 0.131
As reported in the abstract
Secondary outcomes
- PDNV incidence, day of surgery — PDNV incidence, palonosetron vs placebo · no significant difference
- 47% vs 56% · P = 0.31
- PDNV incidence, POD 1 — PDNV incidence, palonosetron vs placebo · significant difference
- 18% vs 34% · P = 0.033
- PDNV incidence, POD 2 — PDNV incidence, palonosetron vs placebo · significant difference
- 9% vs 27% · P = 0.007
- PDNV incidence, POD 3 — PDNV incidence, palonosetron vs placebo · no difference
- 15% vs 13% · P = 0.700
Original publication
Palonosetron as prophylaxis for post-discharge nausea and vomiting: a prospective, randomised, double-blind, placebo-controlled trial in ambulatory surgery. Br J Anaesth. Published 26 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →